Annabel Meireson
- ORCID iD
-
0000-0002-8303-3072
Show
Sort by
-
- PhD Thesis
- open access
Biomarkers in immuno-oncology : from melanoma to other cancer types, from tissue to liquid biopsy, from late stage to early stage disease
(2022) -
- Journal Article
- A1
- open access
Clinical relevance of serum Kyn/Trp ratio and basal and IFN gamma-upregulated IDO1 expression in peripheral monocytes in early stage melanoma
-
- Journal Article
- A1
- open access
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial
-
- Journal Article
- A1
- open access
Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures
-
- Journal Article
- A1
- open access
IDO expression in cancer : different compartment, different functionality?
-
Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma
-
Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results
-
Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results
-
Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma
-
- Journal Article
- A1
- open access
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma